Suggested remit - To appraise the clinical and cost effectiveness of entrectinib within its proposed marketing authorisation for treating NTRK fusion-positive advanced solid tumours
 
Status In progress
Process STA 2018
ID number 1512

Provisional Schedule

Committee meeting 20 November 2019
Expected publication 01 April 2020

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Roche (entrectinib)
  Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
  Sarcoma UK

Commentators

Associated public health groups Public Health England
  Public Health Wales
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Kidney Patients Association
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
08 March 2019 Invitation to participate
14 November 2018 - 12 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance